Kura Oncology (NASDAQ:KURA) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research note issued to investors on Saturday.

Several other analysts have also recently commented on KURA. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a report on Tuesday, January 13th. Wedbush reissued an “outperform” rating and issued a $38.00 target price (up from $36.00) on shares of Kura Oncology in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, January 22nd. Leerink Partners set a $20.00 price target on shares of Kura Oncology and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Finally, Barclays reissued an “overweight” rating and set a $28.00 price objective (up from $11.00) on shares of Kura Oncology in a research note on Monday, November 24th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.00.

Kura Oncology Price Performance

Kura Oncology stock opened at $8.31 on Friday. The stock has a market capitalization of $723.14 million, a P/E ratio of -3.35 and a beta of 0.23. Kura Oncology has a 12-month low of $5.41 and a 12-month high of $12.49. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. The firm’s 50-day moving average is $9.38 and its two-hundred day moving average is $9.18.

Insider Buying and Selling

In other Kura Oncology news, SVP Thomas James Doyle sold 7,142 shares of the company’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $60,421.32. Following the completion of the transaction, the senior vice president owned 145,167 shares in the company, valued at $1,228,112.82. This represents a 4.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian T. Powl sold 6,414 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $54,262.44. Following the completion of the sale, the insider directly owned 183,275 shares of the company’s stock, valued at $1,550,506.50. This trade represents a 3.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 59,794 shares of company stock valued at $537,176. 6.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. IFP Advisors Inc increased its stake in Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after buying an additional 1,284 shares during the period. EverSource Wealth Advisors LLC boosted its position in Kura Oncology by 392.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after buying an additional 3,072 shares during the last quarter. Allworth Financial LP grew its stake in shares of Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after acquiring an additional 1,553 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Kura Oncology by 127.2% during the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after acquiring an additional 3,769 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after acquiring an additional 9,958 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.